KRAS and neoplasm: We found significantly lower enrichment levels in 13 pathways within the KRAS-mutated group: pDCs, Treg, inflammation-promoting, Th1 cells, HLA, T cell co-stimulation, cytolytic activity, tumor infiltration lymphocyte (TIL), T cell co-inhibiting, T helper cells, neutrophils, macrophages, and checkpoint (Supplementary Table 3).